-
1.发明公开TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR 审中-公开百日咳ON BS BS IT IT IT TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
公开(公告)号：EP2958943A1
公开(公告)日：2015-12-30
申请号：EP14713280.7
申请日：2014-02-20
申请人： The Trustees of The University of Pennsylvania , University of Pittsburgh - Of the Commonwealth System of Higher Education , Novartis AG
发明人： BROGDON, Jennifer , LOEW, Andreas , JOHNSON, Laura Alexandra , JUNE, Carl H. , MAUS, Marcela , SCHOLLER, John , OKADA, Hideho
CPC分类号： C07K16/2863 , A61K35/17 , A61K38/00 , A61K2039/505 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
摘要翻译： 本发明提供用于治疗与EGFRvIII表达相关的疾病的组合物和方法。 本发明还涉及对EGFRvIII特异性的嵌合抗原受体（CAR），编码它的载体和包含抗-EGFRVIII CAR的重组T细胞。 本发明还包括施用表达CAR的遗传修饰的T细胞的方法，其包含抗EGFRvIII结合结构域。
-
公开(公告)号：EP3626741A1
公开(公告)日：2020-03-25
申请号：EP19196212.5
申请日：2014-02-20
申请人： The Trustees of The University of Pennsylvania , University of Pittsburgh - Of the Commonwealth System of Higher Education , Novartis AG
发明人： BROGDON, Jennifer , LOEW, Andreas , JOHNSON, Laura Alexandra , JUNE, Carl H. , MAUS, Marcela , SCHOLLER, John , OKADA, Hideho
摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
-
公开(公告)号：EP2958943B1
公开(公告)日：2019-09-11
申请号：EP14713280.7
申请日：2014-02-20
申请人： The Trustees of The University of Pennsylvania , University of Pittsburgh - Of the Commonwealth System of Higher Education , Novartis AG
-
公开(公告)号：EP4420663A3
公开(公告)日：2024-10-30
申请号：EP24173692.5
申请日：2014-12-19
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783 , A61K31/436 , A61K35/17 , C07K14/725 , C07K16/28
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：EP4406610A3
公开(公告)日：2024-10-30
申请号：EP24166976.1
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61K39/00 , A61K35/17 , A61K31/436 , A61P35/02
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
6.发明公开
公开(公告)号：EP3172237A2
公开(公告)日：2017-05-31
申请号：EP15753519.6
申请日：2015-07-21
发明人： BROGDON, Jennifer , CHOI, Eugene , EBERSBACH, Hilmar , GLASS, David , HUET, Heather , JUNE, Carl H. , MANNICK, Joan , MILONE, Michael C. , MURPHY, Leon , PLESA, Gabriela , RICHARDSON, Celeste , RUELLA, Marco , SINGH, Reshma , WANG, Yongqiang , WU, Qilong
CPC分类号： C07K14/705 , A61K35/12 , A61K38/177 , C07K16/2878 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
摘要翻译： 本发明提供了用于治疗与BCMA表达相关的疾病的组合物和方法。 本发明还涉及对编码BCMA载体的BCMA载体特异性的嵌合抗原受体（CAR）和包含BCMA CAR的重组T细胞。 本发明还包括施用表达包含BCMA结合结构域的CAR的遗传修饰的T细胞的方法。
-
公开(公告)号：EP3171882A1
公开(公告)日：2017-05-31
申请号：EP15744448.0
申请日：2015-07-21
发明人： KENDERIAN, Saad , BROGDON, Jennifer , EBERSBACH, Hilmar , GILL, Saar , GLASS, David , JASCUR, Julia , MANNICK, Joan , MILONE, Michael, C. , MURPHY, Leon , RICHARDSON, Celeste , SINGH, Reshma , WEI, Lai , WU, Qilong , YANG, Qiumei , ZHANG, Jiquan
IPC分类号： A61K35/17 , C07K14/725 , C07K16/28
CPC分类号： A61K39/0011 , A61K31/7068 , A61K35/17 , A61K45/06 , A61K2039/5156 , C07K14/7051 , C07K14/70578 , C07K16/2851 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
摘要翻译： 本发明提供了用于治疗与CLL-1表达相关的疾病的组合物和方法。 本发明还涉及对CLL-1特异性的嵌合抗原受体（CAR），编码它的载体和包含CLL-1 CAR的重组细胞。 本发明还包括施用表达包含CLL-1结合结构域的CAR的基因修饰细胞的方法。
-
8.发明公开EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS 审中-公开与嵌合抗CD123抗原受体有效的定位PRIMARY人白血病修饰的T细胞
公开(公告)号：EP2958942A1
公开(公告)日：2015-12-30
申请号：EP14711341.9
申请日：2014-02-20
发明人： BROGDON, Jennifer , GILL, Saar , JUNE, Carl, H. , KALOS, Michael, D. , LOEW, Andreas , SCHOLLER, John
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , A61K39/00
摘要： The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
摘要翻译： 本发明提供了组合物和方法用于治疗白血病的，例如，急性髓性白血病（AML）和B细胞急性淋巴性白血病（B-ALL）。 因此，本发明涉及特异于CD123至少一种嵌合抗原受体（CAR），载体包含相同和重组的T细胞，其包括的CD123 CAR。 因此，本发明包括施用表达CAR做了遗传修饰的T细胞包括CD123结合结构域的方法。 因此，本发明包括骨髓消融治疗中迫使骨髓或修复移植的使用方法。
-
公开(公告)号：EP4420663A2
公开(公告)日：2024-08-28
申请号：EP24173692.5
申请日：2014-12-19
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： A61K31/436
CPC分类号： C07K14/7051 , C07K14/70521 , C07K14/70539 , C07K14/70578 , C12N9/90 , C07K2319/0020130101 , C07K2319/0320130101 , C07K2319/7020130101 , C12N9/1205 , C07K2319/4120130101 , C07K2319/4320130101 , A61K31/436 , C12Y502/00 , A61P35/00 , A61P37/04 , A61K39/464468 , A61K2239/2420230501 , A61K2239/4820230501 , A61K39/4631 , A61K39/464404 , A61K2239/2320230501 , A61K39/4611 , A61K2239/3820230501 , A61K39/464412
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
10.发明授权
公开(公告)号：EP2958942B1
公开(公告)日：2020-06-03
申请号：EP14711341.9
申请日：2014-02-20
发明人： BROGDON, Jennifer , GILL, Saar , JUNE, Carl, H. , KALOS, Michael, D. , LOEW, Andreas , SCHOLLER, John
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , A61K39/00 , A61K38/17
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.044 秒)
